Goldman Sachs
IRWD icon

Goldman Sachs’s Ironwood Pharmaceuticals IRWD Stock Holding History

Goldman Sachs’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40,596
Closed -$628K – 5458
2018
Q3 		$628K Hold
40,596
– – ﹤0.01% 4300
2018
Q2 		$650K Buy
+40,596
New +$601K ﹤0.01% 4353
2017
Q2 		– Sell
-31,999
Closed -$457K – 6853
2017
Q1 		$457K Buy
+31,999
New +$438K ﹤0.01% 5113
2016
Q1 		– Sell
-82,267
Closed -$799K – 7192
2015
Q4 		$799K Sell
82,267
-37,133
-31% -$359K ﹤0.01% 4507
2015
Q3 		$1.04M Buy
119,400
+1,194
+1% +$11.1K ﹤0.01% 4439
2015
Q2 		$1.19M Buy
+118,206
New +$1.37M ﹤0.01% 4374
2014
Q4 		– Sell
-358,200
Closed -$3.89M – 7206
2014
Q3 		$3.89M Buy
358,200
+59,700
+20% +$683K ﹤0.01% 3269
2014
Q2 		$3.83M Hold
298,500
– – ﹤0.01% 3321
2014
Q1 		$3.08M Buy
298,500
+179,100
+150% +$2.01M ﹤0.01% 3562
2013
Q4 		$1.16M Sell
119,400
-119,400
-50% -$1.07M ﹤0.01% 4596
2013
Q3 		$2.37M Buy
238,800
+77,610
+48% +$761K ﹤0.01% 3757
2013
Q2 		$1.34M Buy
+161,190
New +$1.95M ﹤0.01% 4127

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's IRWD Position: Q1 2026 in Review

Goldman Sachs increased its Ironwood Pharmaceuticals (IRWD) stake by 111% in Q1 2026, buying an estimated $5.8M and bringing the position to 2,690,634 shares worth $9.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Goldman Sachs first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.2M in Q3 2021. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Goldman Sachs held 2,690,634 shares of Ironwood Pharmaceuticals worth $9.44M as of Q1 2026.
  • Goldman Sachs bought 1,415,319 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $5.8M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3119 holding.
  • Goldman Sachs first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Ironwood Pharmaceuticals position peaked at $40.2M in Q3 2021.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.